相关实验视频

Updated: Jul 10, 2025

Experimental Melanoma Immunotherapy Model Using Tumor Vaccination with a Hematopoietic Cytokine

Experimental Melanoma Immunotherapy Model Using Tumor Vaccination with a Hematopoietic Cytokine

Published on: February 24, 2023

新辅助化疗和新辅助化疗与免疫疗法导致不同瘤收缩模式在三阴性乳腺癌

Jiachen Zou^1,2, Liulu Zhang³, Yuanqi Chen⁴

¹Department of The First Clinical Medicine, Guangdong Medical University, Zhanjiang, China.

Journal of breast cancer

|November 20, 2023

概括

新辅助化疗与免疫疗法 (NACI) 在三阴性乳腺癌 (TNBC) 中显示出扩散性下降瘤缩模式比单独化疗 (NAC) 更频繁. 所有观察到的收缩模式都表明,在NACI治疗后,病理完整反应率很高.

科学领域:

在瘤学瘤学.
放射学放射学是一门学科.
医疗成像医学成像

背景情况:

三重阴性乳腺癌 (TNBC) 提出了独特的治疗挑战.
新辅助化疗 (NAC) 是TNBC的标准治疗方法.
免疫疗法添加到NAC (NACI) 是一个不断发展的治疗策略.

研究的目的:

为了在TNBC患者中比较NACI和NAC之间的MRI上的瘤缩模式.
研究观察到的瘤缩模式与治疗疗效 (病理完整反应 - pCR) 之间的关系.

主要方法:

对99名接受NAC或NACI治疗的TNBC患者的回顾性分析 (2019年1月至2021年7月).
在治疗前和后的MRI上对瘤收缩模式的分类,分为集中收缩 (CS),分散减少或没有变化.
治疗组之间的收缩模式的比较和与pCR率的相关性评估.

主要成果:

与NAC组相比,NACI组 (68%) 的扩散性下降模式更频繁 (36%).
在治疗方案和瘤缩模式之间发现了统计学上显著的关联 (p=0.004).
NACI组的pCR率 (82%) 比NAC组 (45%) (p<0.001) 高得多.

结论:

与TNBC中的NAC相比,NACI与扩散减少瘤缩模式的发病率更高有关.
所有已识别的瘤缩模式与接受NACI治疗TNBC的患者的高PCR率相关.

关键词:

免疫治疗是一种免疫疗法.磁共振成像是一种磁共振成像技术.新辅助疗法是一种新辅助疗法.三重阴性乳腺新生体

更多相关视频

Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer

Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer

Published on: February 12, 2017

Studying Triple Negative Breast Cancer Using Orthotopic Breast Cancer Model

Studying Triple Negative Breast Cancer Using Orthotopic Breast Cancer Model

Published on: March 20, 2020

相关概念视频

Tumor Immunotherapy

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.